Application of naringin in preparation of medicine for treating chronic obstructive pulmonary disease

A technology for chronic obstructive pulmonary disease and naringin, which is applied in drug combinations, respiratory diseases, pharmaceutical formulations, etc., can solve the problem of limited reduction in the frequency of acute exacerbations in patients

Pending Publication Date: 2022-05-27
SUN YAT SEN UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are many pharmacological and non-pharmacological interventions available to prevent COPD exacerba

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of naringin in preparation of medicine for treating chronic obstructive pulmonary disease
  • Application of naringin in preparation of medicine for treating chronic obstructive pulmonary disease
  • Application of naringin in preparation of medicine for treating chronic obstructive pulmonary disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Example 1. Effect of naringin on lung function of COPD model mice

[0012] Forty-eight male ICR mice (SPF grade) weighing about 20 g were randomly divided into six groups, with 8 mice in each group. Set as normal control group, model group, naringin low, middle and high dose groups (30, 60, 120 mg / kg) and positive control group. The mice were adapted to the feeding for 1 week, and then the mice were injected with 10% chloral hydrate by intraperitoneal injection. The mice were anesthetized and placed supine on the inclined frame at a 45° angle. The oral cavity of the mice was opened with a tongue depressor, and the glottis was found. A special microinjection syringe was used to insert the trachea to the lungs through the glottis, and DPM (0.5 mg / mice, 50 μL / mice) was instilled. Keep it for 1-2min to make the DPM spread evenly. The doses of naringin were 30, 60, and 120 mg / kg (calculated based on the prepared dry powder), and the dose of roflumilast in the positive cont...

Embodiment 2

[0018] Example 2. The effect of naringin on the pathological changes of lungs in COPD model mice

[0019] The experimental grouping, modeling method and administration method were the same as those in Example 1.

[0020] Histopathological observation of mouse lung tissue: slices were made and stained with hematoxylin-eosin to observe the pathological changes of mouse lung tissue.

[0021] Experimental results: In the normal group, the lung tissue structure of the mice was regular, the alveoli were evenly distributed, the alveolar wall was intact without obvious collapse, the tracheal wall was intact without thickening, and there was no obvious inflammatory cell aggregation and bleeding sites in the tissue. Compared with the normal group mice, the lung structure of the model group mice was significantly changed, including: obvious alveolar wall collapse, tracheal wall thickening, inflammatory cell accumulation near the particle deposition, hemorrhage caused by tissue damage, th...

Embodiment 3

[0022] Example 3. The effect of naringin on the number of blood leukocytes in COPD model mice

[0023] The experimental grouping, modeling method and administration method were the same as those in Example 1.

[0024] Orbital blood collection and leukocyte division count of mice: Cut the whiskers on both sides of mice in each group, use elbow tweezers to dig out one eyeball, collect the effluent blood in a blood collection tube containing heparin sodium, and use automatic blood cells The analyzer conducts blood leukocyte differential count, and detects the total number of leukocytes and lymphocytes respectively.

[0025] Experimental results: Compared with the normal group, the total number of leukocytes and lymphocytes in the model group increased (p<0.05). Compared with the model group, the total number of leukocytes and lymphocytes in the naringin administration group were significantly decreased (p<0.05 or p<0.01). The regulatory effect of naringin on the increase of leu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a novel application of naringin in preparation of a medicine for treating chronic obstructive pulmonary disease. In particular to application of naringin in preparation of drugs for treating chronic obstructive pulmonary diseases induced by diesel PM2.5 particles, including preparation of drugs for treating lung tissue elastic resistance reduction, lung tissue airway resistance increase or lung tracheal wall or alveolar cavity thickening induced by diesel PM2.5 particles. Tests prove that the naringin can be used as a medicinal active component and can be matched with a pharmaceutically acceptable carrier, so that a basis is provided for preventing and treating the chronic obstructive pulmonary disease, and the life quality of a patient is improved.

Description

technical field [0001] The invention relates to the pharmaceutical application of naringin, in particular to the application of naringin in preparing a medicine for treating chronic obstructive pulmonary disease. Background technique [0002] Naringin is an effective monomer extracted from the medicinal material Huatangerine, which is widely found in Rutaceae citrus plants, and has significant antitussive, phlegm-relieving, anti-inflammatory and antioxidant effects. The structure of naringin is as follows: [0003] [0004] Chronic obstructive pulmonary disease (COPD) is a lung disease characterized by airflow limitation that is not fully reversible and progresses progressively. or abnormal inflammatory responses to harmful particles. With the repeated attacks and acute exacerbations of the disease, the lung function gradually declines, and there is a feeling of shortness of breath during daily activities and even at rest. COPD has a high incidence, is more common in t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61K36/752A61P11/00
CPCA61K31/7048A61K36/752A61P11/00
Inventor 师瑞吴灏苏薇薇王永刚
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap